Transplant Biomarker Risk Stratification Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is Transplant Biomarker Risk Stratification Market in 2026?

USD 1,129.5 million in 2026 and USD 4,042.8 million by 2036 at a 13.6% CAGR.

Demand for transplant biomarker risk stratification is projected to expand at 13.6% CAGR from 2026 to 2036, supported by recurring surveillance across growing recipient populations. The industry valuation is forecast to rise from USD 1,129.5 million in 2026 to USD 4,042.8 million by 2036. Transplant programs combine transplant diagnostics with clinical findings to identify graft injury risk earlier during routine follow-up. United Network for Organ Sharing reported in January 2026 that United States hospitals completed 49,064 organ transplants during 2025. The larger treated population creates recurring laboratory demand across stable surveillance and urgent evaluation pathways. Commercial growth depends on reports that connect each biomarker result with a defined biopsy or treatment decision.

National adoption routes differ even though laboratories may use similar molecular methods across transplant programs. The USA offers broad commercial service access, whereas the UK relies more heavily on national evidence review and public procurement. Germany and South Korea use specialist hospital infrastructure, although reimbursement and imported assay dependence create different commercial frictions. Kidney programs can support frequent testing, but heart and lung services often require broader interpretation across smaller recipient groups. The molecular diagnostics supports assay development across these pathways without establishing transplant-specific clinical value. Biopharmaceutical sponsors also connect surveillance with companion diagnostics programs that evaluate treatment response across defined transplant cohorts. Clinical laboratories need dependable specimen logistics and interpretation support that fit each country's established care pathway.

Summary of the Transplant Biomarker Risk Stratification Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Market growth depends on transplant programs identifying graft injury earlier without adding unmanaged diagnostic work across specialist care pathways. The market is projected to expand, supported by recurring molecular surveillance across recipient populations. Blood-based monitoring creates repeat testing volume across kidney and other solid-organ pathways with established specialist oversight. Reimbursement and clinical protocols determine whether validated assays become routine purchases rather than occasional specialist tests. Turnaround time and clear action thresholds shape commercial value across centers managing complex immunosuppression decisions.
Product and Segment View	Commercial value begins with biomarker signals that connect clearly with one clinical decision inside an established transplant pathway. Donor-derived cell-free DNA is projected to hold 35.3% share in 2026, reflecting its direct relationship with measurable allograft injury. Acute rejection risk assessment is forecast to represent 33.9% share in 2026, supported by its position near biopsy decisions. Kidney transplantation is estimated to account for 34.2% share in 2026, owing to large procedure volume and established follow-up. Transplant centers are expected to capture 38.9% share in 2026, enabled by concentrated expertise and coordinated laboratory ordering.
Geography and Growth Outlook	Country adoption reflects different payment structures and laboratory service routes despite common interest in noninvasive surveillance. The USA is forecast to expand at 15.3% CAGR through 2036, aided by established transplant networks and commercial laboratory access. Germany is projected to record 14.7% CAGR during the assessment period, underpinned by specialist infrastructure and regulated adoption. South Korea is anticipated to post 14.1% CAGR through 2036, strengthened by centralized oversight and tertiary hospital laboratories. Japan and the UK are estimated at 13.6% and 12.5% CAGR through 2036, reflecting different validation and procurement environments.
Competitive Landscape	Competition spans centralized clinical laboratories and transplant diagnostics manufacturers alongside specialist molecular risk platforms across several organ pathways. CareDx and Natera provide commercial dd-cfDNA services with specimen logistics and clinician-facing reports across transplant pathways. Verici Dx and Insight Molecular Diagnostics use different RNA and digital PCR methods for specialized rejection assessment. Eurofins Viracor connects immune profiling with post-transplant reference testing for complex recipient management across specialist laboratory workflows. Thermo Fisher Scientific and Werfen provide broader laboratory infrastructure that requires exact transplant workflow validation.
Analyst Perspective	The commercial test is whether each biomarker service changes a documented clinical decision without creating unmanaged interpretation work. Transplant centers should measure avoided unnecessary biopsies separately from earlier injury detection; each outcome carries different financial value. Assay providers need dependable specimen logistics and specialist support across routine surveillance and urgent evaluation pathways. A practical launch needs defined testing cadence and escalation ownership for expansion across additional organs or clinical sites. - Anurag Sharma, Principal Analyst at Future Market Insights

Source: FMI's proprietary forecasting model and primary research

How is the transplant biomarker risk stratification market segmented?

The transplant biomarker risk stratification industry is segmented by biomarker type; application; organ type; end user; and region.

The segmentation framework separates biological signals from the clinical decisions and care settings that use them. Biomarker type covers donor-derived cell-free DNA and gene expression alongside protein and multi-omics approaches within laboratory portfolios. Application analysis distinguishes acute rejection assessment from graft survival prediction and immunosuppression optimization across clinical programs. Organ analysis separates kidney pathways from heart and lung or liver transplantation due to different surveillance burdens. End-user categories distinguish transplant centers from hospitals and diagnostic laboratories alongside academic research institutes and specialized care teams. Regional analysis tracks payment and service availability across health systems with different transplant volumes and reimbursement structures.

What supports demand for Donor-derived Cell-free DNA (dd-cfDNA) within the Biomarker Type category?

Donor-derived cell-free DNA gives kidney programs a blood-based measure of graft injury that can complement creatinine trends and biopsy findings. A multicenter registry analysis published in August 2025 evaluated 1,070 kidney transplant biopsies from 1,743 recipients. Elevated dd-cfDNA results were associated with greater rejection yield across surveillance and for-cause biopsies in the registry. The related liquid biopsy testing market supports scalable blood collection, although transplant decisions require organ-specific clinical interpretation.

• Donor-derived cell-free DNA is projected to hold 35.3% share within biomarker type in 2026 owing to its direct connection with measurable allograft injury. Repeated blood collection supports scheduled surveillance and targeted review without making every recipient undergo an invasive procedure. Clear action thresholds determine whether each result changes biopsy timing or prompts a focused treatment review.
• Transplant centers use dd-cfDNA during scheduled surveillance and targeted evaluation for unexplained graft dysfunction across kidney programs. Adoption requires consistent collection timing and reliable specimen transport across outpatient networks serving each transplant program. Specialist review must place each result within the full clinical record due to possible elevations from infection or unrelated injury.

How does Acute Rejection Risk Assessment shape demand within the Application category?

Acute rejection risk assessment converts molecular findings into a time-sensitive decision about biopsy or immunosuppression review. Longitudinal testing helps clinicians distinguish a resolving episode from persistent injury that requires closer management. A useful report must combine biomarker movement with kidney function and antibody findings across each clinical review. Integrated interpretation reduces isolated threshold decisions and supports consistent escalation across the complete transplant care team.

• Acute rejection risk assessment is likely to capture 33.9% share within application in 2026 attributable to its position near urgent biopsy and treatment decisions. Risk reports separate routine surveillance from findings that justify additional evaluation across coordinated specialist services. Commercial value depends on reducing uncertainty without presenting one biomarker threshold as a complete diagnosis.
• Hospitals use acute rejection tools within clinical diagnostics workflows to prioritize biopsy capacity for recipients whose graft indicators change. A July 2025 prospective study enrolled 488 kidney recipients and analyzed 66 participants with biopsy-proven acute rejection. The study linked post-rejection dd-cfDNA patterns with twelve-month outcomes, supporting repeated interpretation rather than one isolated result.

How is Kidney Transplantation positioned within the Organ Type category?

Kidney transplantation creates sustained biomarker monitoring demand through long follow-up across large outpatient recipient populations. Creatinine changes may identify graft dysfunction without explaining the underlying injury process or its clinical urgency. Kidney programs therefore combine molecular signals with antibody testing and pathology across defined escalation pathways. Established HLA typing workflows give these programs a familiar structure for joining biomarker evidence with immunologic risk.

• By organ type, kidney transplantation is estimated to hold 34.2% share in 2026 owing to procedure volume and established laboratory follow-up. United Network for Organ Sharing reported in January 2026 that United States centers completed 27,573 kidney transplants during 2025. The procedure base supports recurring biomarker testing across routine surveillance and suspected injury pathways nationwide.
• Kidney programs often begin biomarker testing among recipients with donor-specific antibodies or unexplained changes in graft function. A focused protocol makes utilization and clinical consequences easier to measure during the first implementation period. Wider adoption requires evidence that testing improves decisions across routine recipients and clearly defined higher-risk groups.

What makes Transplant Centers central to the End User category?

Transplant centers coordinate laboratory orders with pathology review and immunosuppression decisions through specialized multidisciplinary teams. Central ownership can align specimen timing with biopsy review and treatment changes across one accountable service. CMS stated in June 2026 that 95 eligible kidney transplant hospitals would participate at the July 2026 start of performance year two. The model places care coordination and data sharing within the same institutional performance framework for participating hospitals.

• By end user, transplant centers are forecast to represent 38.9% share in 2026 driven by their control over testing cadence and clinical escalation. Coordinated ownership connects biomarker results with biopsy review and medication decisions across one specialist team. The in vitro diagnostics market provides broader laboratory context without replacing transplant-specific workflow validation across regulated health systems.
• Regional hospitals often route samples through a central transplant program instead of building local molecular capacity for limited recipient volumes. Adoption depends on dependable transport and consultation routes that remain available outside routine clinic hours. Service agreements should define result turnaround and specialist responsibility across affiliated hospitals within the network.

What are the drivers, restraints, and opportunities in the transplant biomarker risk stratification market?

Demand rises through repeated graft surveillance, but interpretation uncertainty restrains routine use and integrated reporting creates a practical service opportunity.

• Driver: Repeated surveillance supports earlier graft-injury review and directs limited biopsy capacity toward recipients with stronger evidence of actionable risk.
• Restraint: Biomarker elevation can reflect several forms of graft injury and requires clinical context for a defensible rejection assessment.
• Opportunity: Integrated reports can combine molecular signals with clinical variables and reduce intermediate classifications that complicate transplant decisions.

Earlier risk recognition supports testing demand by helping clinicians distinguish stable follow-up from recipients who need closer evaluation. A May 2026 study analyzed 922 plasma samples and improved classification by combining dd-cfDNA with clinical parameters. The combined model reclassified many samples that initially occupied an intermediate rejection-risk category during clinical assessment. Transplant programs can direct limited biopsy capacity toward recipients carrying stronger evidence of actionable allograft injury.

The inability to distinguish one pathological process from broader graft injury limits routine dd-cfDNA interpretation. Clinical teams need infection data and antibody findings alongside each molecular result used for rejection assessment. A December 2025 review identified difficulty separating different forms of graft damage as a principal limitation. Laboratories without contextual support may add review work and weaken confidence in repeated surveillance testing.

Integrated reporting creates a service opening by applying multiplex diagnostics methods to organ-specific thresholds and documented escalation pathways. CareDx launched AlloSure Plus in July 2025 following validation using more than 2,700 renal transplant biopsies. The platform combines dd-cfDNA with traditional clinical variables and supports electronic integration through Epic Aura. Transplant companies can differentiate through longitudinal interpretation and specialist consultation rather than compete through assay sensitivity alone.

Which country CAGRs are profiled in the transplant biomarker risk stratification market?

Country	CAGR
USA	15.3%
UK	12.5%
Germany	14.7%
Japan	13.6%
South Korea	14.1%

How do country-level CAGRs compare in the transplant biomarker risk stratification market?

The country forecast covers a 2.8 percentage-point range, which shows measured separation and not sharply different growth trajectories. The USA and Germany form a close upper cluster separated by 0.6 percentage points across the ten-year assessment period. South Korea sits 0.6 points below Germany and 0.5 points above Japan, creating a compact middle transition. Japan remains near that middle group and the UK sits 1.1 percentage points lower through 2036. The forecast gaps describe momentum instead of current market size or established testing volume across each national health system.

• The USA offers broad commercial laboratory access, although coverage differences can produce uneven adoption outside major transplant networks.
• Germany combines specialist laboratory capacity with hospital-led validation, so market entry depends on reimbursement alignment across federal care settings.
• South Korea pairs centralized oversight with advanced tertiary hospitals, yet imported assay dependence can affect pricing and service continuity.
• Japan supports disciplined surveillance through concentrated expertise and requires local evidence for living-donor pathways and purchasing approval.
• The UK uses nationally coordinated pathways, but public procurement requires service-level evidence that demonstrates measurable clinical or capacity benefits.

Similar growth rates can produce different launch economics due to varied payment routes and laboratory service models. Assay providers must match local evidence requirements with specimen logistics and specialist support instead of treating the forecast table as an entry ranking. The full report provides country-level CAGR analysis across North America; Latin America; Europe; East Asia; South Asia; Oceania; and the Middle East and Africa.

Country-wise Analysis

• United States transplant programs can order commercial dd-cfDNA services through national reference laboratories that support recurring outpatient surveillance. Demand for the transplant biomarker risk stratification market in the USA is forecast to rise at 15.3% CAGR over the forecast period, supported by extensive kidney follow-up and established laboratory access. The Health Resources and Services Administration reported in April 2026 that more than 100,000 people remained on the national transplant waiting list. Medicare coverage for defined molecular uses supports adoption, although smaller programs may face long transport routes and uneven local interpretation capacity. Commercial entry therefore requires reliable courier coverage and specialist consultation that reaches affiliated hospitals outside major transplant hubs.
• United Kingdom transplant services operate through nationally coordinated pathways that centralize specialist decisions across a limited number of major programs. The UK transplant biomarker risk stratification sector is projected to record 12.5% CAGR during the assessment period, shaped by national evidence review and coordinated laboratory purchasing. National laboratory coordination can standardize collection and reporting across major transplant programs within the public health service. NHS Blood and Transplant reported in July 2025 that 8,096 patients were active on the waiting list at March 31, 2025. Providers need pathway-level outcome data and predictable pricing to pass formal procurement review despite continuing budget competition.
• German transplant care is concentrated in university hospitals that can validate new assays within established molecular laboratory services. Adoption of transplant biomarker risk stratification services in Germany is estimated to expand at 14.7% CAGR through 2036, enabled by university hospital laboratories and specialist transplant programs. Deutsche Stiftung Organtransplantation reported in January 2026 that 985 deceased donors enabled distribution of 3,020 organs during 2025. Specialist infrastructure supports technical training and controlled implementation across federal states with different hospital decision processes. Commercial expansion depends on reimbursement alignment and local validation plans that fit each hospital's diagnostic governance.
• Japanese kidney transplant care relies heavily on living donation and concentrated programs that demand locally validated interpretation. Japan's transplant biomarker risk stratification market outlook is anticipated to advance at 13.6% CAGR over the assessment period, reflecting disciplined surveillance and advanced laboratory practice. Local laboratories need assay performance data that directly reflects Japanese recipients and established clinical practice. Japan Organ Transplant Network reported that 14,983 people remained registered for kidney transplantation on June 30, 2026. A June 2025 multicenter study evaluated dd-cfDNA among 73 living-donor recipients and supported local clinical interpretation. Limited deceased-donor volume and validation expectations require detailed clinical support for each specialist purchasing decision.
• South Korean transplant services operate through tertiary hospitals that follow detailed national rules for donation and post-transplant management. Sales of transplant biomarker risk stratification services in South Korea are forecast to expand at 14.1% CAGR by 2036, facilitated by tertiary hospital laboratories and centralized oversight. The National Institute of Organ, Tissue and Blood Management issued its eleventh revised transplant management guidance in February 2025 for participating institutions. Centralized guidance supports consistent documentation and specialist training across major hospitals, but imported assay dependence can raise pricing and service risks. Market entry requires local technical support and documentation that align with hospital procurement and national clinical requirements.

Who are the notable companies in the transplant biomarker risk stratification market?

CareDx; Natera; Verici Dx; Insight Molecular Diagnostics; Eurofins Viracor; Thermo Fisher Scientific; Omixon; and Werfen are notable companies shaping this market.

The competitive field combines centralized clinical testing with assay kits and transplant-specific interpretation platforms across several organ pathways. CareDx and Natera provide commercial dd-cfDNA services through established laboratory routes and detailed clinician-facing reports. Verici Dx uses RNA signatures, whereas Insight Molecular Diagnostics develops digital PCR products and decentralized testing models. A June 2025 SEC filing confirmed that Oncocyte changed its legal name to Insight Molecular Diagnostics. Eurofins Viracor provides specialty reference testing across immune and infection workflows for complex transplant recipients. Thermo Fisher Scientific and Werfen supply broader automated molecular testing infrastructure across global laboratories serving transplant programs. Omixon adds HLA sequencing and NGS interpretation workflows within Werfen's transplant portfolio for specialist laboratories.

• CareDx and Natera compete through centralized dd-cfDNA services that combine specimen logistics with clinician-facing interpretation. Verici Dx adds RNA-based risk scoring through a specialized kidney transplant laboratory model for clinical programs. Selection depends on evidence for defined clinical decisions rather than assay availability across transplant programs.
• Insight Molecular Diagnostics and Eurofins Viracor support testing through digital PCR or specialty reference laboratory services. Their portfolios connect rejection monitoring with existing antibody and infection workflows across complex transplant recipient care. Routine use depends on reimbursement access and dependable consultation throughout every participating clinical service region.
• Thermo Fisher Scientific and Werfen provide immunogenetics infrastructure plus post-transplant tools through established laboratory channels. Omixon adds HLA sequencing and dd-cfDNA products within Werfen's transplant portfolio for specialized histocompatibility laboratories. Platform breadth supports integration but each capability requires direct validation inside the defined rejection-monitoring workflow.

Competitive Benchmarking: Transplant Biomarker Risk Stratification Market

Company	Molecular Rejection Monitoring	Pre-transplant Immune Profiling	Clinical Interpretation Support	Geographic Reach
CareDx	High	Low	High	United States
Natera	High	Low	High	United States and selected research markets
Verici Dx	High	High	High	United States
Insight Molecular Diagnostics	High	Low	Medium	United States and selected research markets
Eurofins Viracor	High	High	Medium	United States
Thermo Fisher Scientific	Medium	High	Medium	Global
Omixon (Werfen)	Medium	High	Medium	Europe and selected global markets
Werfen (Immucor)	Low	High	Medium	Global

Molecular rejection monitoring receives High for a current clinical service and Medium for a transplant-specific laboratory kit. Low requires a documented transplant portfolio with limited capability for direct molecular rejection monitoring across current products. Pre-transplant immune profiling receives High for dedicated HLA or antibody tools and Medium for partial profiling support. Low requires a verified transplant offer without dedicated pre-transplant immune characterization across its current portfolio. Clinical interpretation support receives High for clinician-facing risk reporting and Medium for specialist laboratory interpretation or software. Low requires documented kit-centered output with limited decision support inside the provider's stated service model.

Source basis: Official corporate pages, regulatory records, and investor materials reviewed through July 2026.

Key Developments in the Transplant Biomarker Risk Stratification Market

• In June 2026, CareDx completed the sale of its Lab Products business to Eurobio Scientific for USD 171.2 million in cash consideration. The transaction transferred HLA typing kits and non-North American monitoring assays following required Swedish regulatory clearance. CareDx retained its core United States testing services and digital solutions; Eurobio gained the global kit business and related distribution responsibilities.
• In June 2026, Natera entered a strategic partnership that selected Prospera as the exclusive dd-cfDNA assay for Eledon's planned Phase 3 kidney transplant trial. The study targets about 600 recipients across more than 100 centers and plans longitudinal surveillance during experimental treatment. The agreement expands Prospera's role within multicenter drug development and standardized transplant monitoring across participating centers.
• In June 2026, Verici Dx received New York State approval for Tutivia and extended authorized laboratory access across all 50 states. The blood-based RNA test classifies kidney recipients as low or high risk for acute rejection. Nationwide availability gives transplant centers a consistent commercial route for using the score during biopsy and treatment review decisions.
• In January 2025, Oncocyte (Insight Molecular Diagnostics) expanded Medicare billing eligibility for VitaGraft Kidney among recipients with newly developed donor-specific antibodies. MolDX confirmed coverage under the existing local coverage determination and assigned the required Z-codes for this defined use. The company now operates as Insight Molecular Diagnostics, and the decision created a clearer reimbursement route for higher-risk surveillance rather than routine testing.

Key Players in the Transplant Biomarker Risk Stratification Market

Clinical Monitoring Service Providers

• CareDx
• Natera
• Verici Dx

Specialty Laboratory and Assay Providers

• Insight Molecular Diagnostics
• Eurofins Viracor
• Thermo Fisher Scientific

Immunogenetics Platform Providers

• Omixon
• Werfen

Transplant Biomarker Risk Stratification Market - Report Scope

Coverage field	Report scope
Market breakdown	Biomarker type; application; organ type; end user; and region.
Quantitative Units	USD Million
Market Definition	Products and services that directly assess molecular or immune biomarkers to stratify rejection and graft-injury risk across solid-organ transplant pathways.
Regions Covered	North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; and Middle East and Africa.
Countries Covered	USA; UK; Germany; Japan; and South Korea.
Key Companies Profiled	CareDx; Natera; Verici Dx; Insight Molecular Diagnostics; Eurofins Viracor; Thermo Fisher Scientific; Omixon; and Werfen
Forecast Period	2026 to 2036.
Approach	Hybrid bottom-up and top-down market sizing supported by primary interviews and official desk research.

Transplant Biomarker Risk Stratification Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Transplant Biomarker Risk Stratification Market by Segments

Transplant Biomarker Risk Stratification Market segmented by Biomarker Type:

• Donor-derived Cell-free DNA (dd-cfDNA)
• Gene Expression Biomarkers
• Protein Biomarkers
• Multi-omics Biomarkers

Transplant Biomarker Risk Stratification Market segmented by Application:

• Acute Rejection Risk Assessment
• Graft Survival Prediction
• Immunosuppression Optimization
• Post-transplant Surveillance

Transplant Biomarker Risk Stratification Market segmented by Organ Type:

• Kidney Transplantation
• Heart Transplantation
• Lung Transplantation
• Liver Transplantation

Transplant Biomarker Risk Stratification Market segmented by End User:

• Transplant Centers
• Hospitals
• Diagnostic Laboratories
• Academic & Research Institutes

Transplant Biomarker Risk Stratification Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• United Network for Organ Sharing. (2026, January 28). USA surpasses 49,000 organ transplants while deceased organ donations dip.
• Centers for Medicare & Medicaid Services. (n.d.). IOTA (Increasing Organ Transplant Access) Model. Retrieved July 21, 2026.
• Health Resources and Services Administration. (2026, April 1). HRSA honors National Donate Life Month, advances organ transplant system modernization.
• NHS Blood and Transplant. (2025, July 9). Organ transplant waiting list hits record high as donor and transplant numbers fall.
• Deutsche Stiftung Organtransplantation. (2026, January 13). Organspendezahlen 2025 auf höchstem Stand seit 2012, dennoch weiterhin großer Bedarf / Deutsche Stiftung Organtransplantation klärt auf: Hohes Alter spricht nicht gegen eine Organspende.
• Japan Organ Transplant Network. (2026, June 30).
• National Institute of Organ, Tissue and Blood Management. (2025, February 27). 2025
• Bromberg, J. S., Brennan, D. C., Taber, D. J., Cooper, M., Anand, S., Akalin, E., Huang, E., Klein, J. A., Glehn-Ponsirenas, R., Rogers, J., Chuang, P., Kothari, A. S., Shen, L., Woodward, R. N., Kumar, D., Wojciechowski, D., Mandelbrot, D., Costa, N., Bu, L., & Weir, M. R. (2025, August 6). Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies. American Journal of Transplantation, 25(12), 2529-2542. DOI: 10.1016/j.ajt.2025.07.2484
• Bunnapradist, S., Leca, N., Zaky, Z. S., Stratta, R. J., Khamash, H. A., Shihab, F., Ekwenna, O., Aldana-Campos, M., Kahwaji, J., Biancone, L., Maw, T. T., Biagini, D. G., Kaur, N., Prewett, A., Gude, G., Van Hummelen, P., Bloom, M. S., Demko, Z., Rabinowitz, M., . . . Qazi, Y. (2025, July 23). Associations between donor-derived cell-free DNA dynamics and clinical outcomes after kidney allograft rejection: A prospective, multicenter study. American Journal of Transplantation, 25(12), 2543-2553. DOI: 10.1016/j.ajt.2025.07.2470
• Pagliazzi, A., Wellekens, K., de Loor, H., Koshy, P., Vaulet, T., Vranken, A., Vanhoutte, T., Kuypers, D., Jallah, B., Jatsenko, T., Kyle, P., Woodward, R., Coemans, M., & Naesens, M. (2026, May 14). Clinical relevance of donor-derived cell-free DNA in monitoring kidney transplant rejection. Journal of the American Society of Nephrology. Advance online publication. DOI: 10.1681/ASN.0000001116
• Salvadori, M., & Rosso, G. (2025, December 18). Utility and limitations of the use of donor-derived cell-free DNA in kidney transplantation. World Journal of Transplantation, 15(4), 104349. DOI: 10.5500/wjt.v15.i4.104349
• Hirai, T., Banno, T., Omoto, K., Shimizu, T., Hidaka, S., Kijima, Y., Furusawa, M., Saitoh, A., Unagami, K., Inui, M., Ishida, H., & Takagi, T. (2025, June 26). Donor-derived cell-free DNA for diagnosing subclinical rejection: A pilot multicenter study in Japanese living-donor kidney transplantation. Clinical Transplantation, 39(7), e70221. DOI: 10.1111/ctr.70221
• CareDx, Inc. (2025, July 31). CareDx announces landmark data in AI-powered transplant diagnostics showcased in over 40 abstracts and 16 oral presentations at the 2025 World Transplant Congress.
• CareDx, Inc. (2026, June 30). CareDx announces completion of sale of Lab Products business to Eurobio Scientific.
• Insight Molecular Diagnostics Inc. (2025, June 17). Oncocyte changes name to Insight Molecular Diagnostics Inc. (iMDx), moves headquarters to Nashville.
• Natera, Inc. (2026, June 25). Natera and Eledon announce strategic partnership for Prospera monitoring in planned Phase 3 kidney transplant trial.
• Verici Dx plc. (2026, June 24). Verici Dx receives New York State approval, establishing nationwide access to Tutivia kidney transplant rejection test.
• Oncocyte Corporation. (2025, January 6). Oncocyte expands market opportunity for VitaGraft Kidney.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations

This Report Answers

• How large is the transplant biomarker risk stratification market in 2026 and 2036?
• Which clinical pressures support recurring transplant biomarker surveillance across organ programs?
• Why does donor-derived cell-free DNA hold the largest biomarker type share in 2026?
• How does acute rejection risk assessment influence biopsy and treatment decisions?
• Why does kidney transplantation account for the largest organ type share in 2026?
• How do country growth rates differ across the USA, UK, Germany, Japan, and South Korea?
• Which companies provide clinical assays, laboratory services, or transplant interpretation platforms?
• What limits routine adoption across reimbursement and clinical workflow settings?
• How can integrated molecular reporting improve risk classification and service economics?